Results 391 to 400 of about 1,463,285 (410)
Some of the next articles are maybe not open access.
Stem Cell Transplantation Methods
2010Just a few short years ago, we still used to think that we were born with a finite number of irreplaceable neurons. However, in recent years, there has been increasingly persuasive evidence that suggests that neural stem cell (NSC) maintenance and differentiation continue to take ace throughout the mammal's lifetime.
Allen L Ho +2 more
openaire +3 more sources
Stem Cell Transplantation for Myelodysplasia
2001The natural course of MDS varies considerably depending upon patient age and findings at the time of diagnosis. Life expectancy ranges from years in early stages to only a few months in advanced stages. The disease can rapidly progress to acute leukemia, and the prognosis for patients with advanced MDS (RAEB, RAEBT) and therapy-related (secondary) MDS ...
H. Joachim Deeg, Hans G. Klingemann
openaire +3 more sources
2011
Hematopoietic stem cell transplant (HSCT) began in humans in the late 1950s and since that time more than 800,000 people have been treated with this procedure. To date 150,000 patients are living 5 years or more post transplant, with this number expanding rapidly [1].
Jean C. Yi +2 more
openaire +2 more sources
Hematopoietic stem cell transplant (HSCT) began in humans in the late 1950s and since that time more than 800,000 people have been treated with this procedure. To date 150,000 patients are living 5 years or more post transplant, with this number expanding rapidly [1].
Jean C. Yi +2 more
openaire +2 more sources
Intestinal stem cell transplantation
Journal of Gastroenterology, 2016Organoid technologies to expand intestinal epithelial cells are gaining increasing attention as a useful tool to investigate many aspects of intestinal epithelial biology and pathology. One important application of organoid systems would be to use intestinal epithelial cells expanded in culture for following transplantation experiments. In this article,
Tetsuya Nakamura, Mamoru Watanabe
openaire +3 more sources
Cytokines in Stem Cell Transplantation
Annals of the New York Academy of Sciences, 1995The use of cytokines in stem cell transplantation is still in the early stages of development. Efficacy has not been established consistently at the present time. When cytokines are employed in the treatment setting, they should be employed in a study setting evaluating whether there has been real patient benefit-palliation without compromise of ...
openaire +3 more sources
Stem cell transplantation for hemoglobinopathies
Current Opinion in Pediatrics, 2003Hereditary anemias caused by beta-thalassemia and sickle cell disease are the most common genetic diseases worldwide. Supportive therapies such as chronic lifelong transfusions, iron chelation for thalassemia, and transfusions or hydroxyurea for sickle cell anemia have significantly ameliorated clinical manifestations of these diseases but cannot ...
Guido Lucarelli, Javid Gaziev
openaire +3 more sources
Neural Transplantation and Stem Cells
2009Recent results have raised important questions on our ability to amplify stem cell populations in sufficient numbers as to be useful for therapy. Several reports have indicated that human stem cell populations harvested from the adult have low or undetectable telomerase levels, age in culture, and may not be propagated indefinitely.
Mohan C. Vemuri, Mahendra S. Rao
openaire +3 more sources
Nonmyeloablative stem cell transplants
Current Opinion in Hematology, 1999Allogeneic stem cell transplantation (SCT) is a curative procedure in a number of hematologic malignancies, but its efficacy is limited by its toxicity, much of which is consequent upon the myeloablative conditioning regimens currently used. The recent demonstration that an immunologically mediated graft-versus-leukemia effect plays a central role in ...
openaire +3 more sources
Alemtuzumab in Stem Cell Transplantation
Medical Oncology, 2002Alemtuzumab, otherwise called CAMPATH-1H, is a humanized monoclonal antibody directed against the CD52 antigen of lymphocytes. It is one of a family of CAMPATH-1 antibodies that have been used over the last 20 yr in stem cell transplantation for depletion of donor and recipient T-cells to prevent graft-versus-host disease and graft rejection.
openaire +3 more sources
Role of Stem Cell Transplantation
Hematology/Oncology Clinics of North America, 2007Hematopoietic stem cell transplantation (SCT) was introduced in the treatment of multiple myeloma in the 1980s. In the autologous setting, the use of peripheral blood stem cells instead of bone marrow has markedly improved feasibility. In fit patients who have normal renal function and are younger than 65 years of age, randomized studies have shown the
openaire +3 more sources